Literature DB >> 22583364

Immunohistochemical verification of ductal differentiation in prostate cancer.

Miklós Tarján1, Anna Lenngren, Dan Hellberg, Tibor Tot.   

Abstract

Recent studies have shown that patients with prostate carcinomas exhibiting ductal differentiation have an unfavourable prognosis compared with those with purely acinar adenocarcinomas. We studied the expression of nine immunohistochemical markers to evaluate their value in delineating carcinomas with and without ductal differentiation. Thirteen tumours showing cellular characteristics and growth patterns typical of ductal differentiation were identified among 110 analysed prostatectomy specimens. The levels of cytoplasmic expression of chromogranine A (69% vs 19%, p = 0.0003) and nuclear expression of p53 (76% vs 12%, p < 0.0001) as well as nuclear expression of Ki-67 (69% vs 26%, p = 0.0047) in the tumour cells, were found to be statistically significantly different in the two tumour categories. Assessment of chromogranine A, p53 and Ki-67 in prostate carcinoma may serve as useful adjunctive diagnostic tools for delineating more aggressive prostate cancer cases exhibiting ductal differentiation.
© 2012 The Authors. APMIS © 2012 APMIS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22583364     DOI: 10.1111/j.1600-0463.2011.02862.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  5 in total

Review 1.  The update of prostatic ductal adenocarcinoma.

Authors:  Tantan Liu; Yingmei Wang; Ru Zhou; Haiyang Li; Hong Cheng; Jing Zhang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

2.  Immunohistochemical profile of ductal adenocarcinoma of the prostate.

Authors:  Amanda H Seipel; Hemamali Samaratunga; Brett Delahunt; Fredrik Wiklund; Peter Wiklund; Johan Lindberg; Henrik Grönberg; Lars Egevad
Journal:  Virchows Arch       Date:  2014-07-25       Impact factor: 4.064

Review 3.  Optimizing the diagnosis and management of ductal prostate cancer.

Authors:  Weranja Ranasinghe; Daniel D Shapiro; Miao Zhang; Tharakeswara Bathala; Nora Navone; Timothy C Thompson; Bradley Broom; Ana Aparicio; Shi-Ming Tu; Chad Tang; John W Davis; Louis Pisters; Brian F Chapin
Journal:  Nat Rev Urol       Date:  2021-04-06       Impact factor: 14.432

4.  Diverse Immunoprofile of Ductal Adenocarcinoma of the Prostate with an Emphasis on the Prognostic Factors.

Authors:  Se Un Jeong; Anuja Kashikar Kekatpure; Ja-Min Park; Minkyu Han; Hee Sang Hwang; Hui Jeong Jeong; Heounjeong Go; Yong Mee Cho
Journal:  J Pathol Transl Med       Date:  2017-08-09

5.  A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.

Authors:  Hiroaki Kobayashi; Takeo Kosaka; Kohei Nakamura; Kazunori Shojo; Hiroshi Hongo; Shuji Mikami; Hiroshi Nishihara; Mototsugu Oya
Journal:  BMC Med Genomics       Date:  2021-10-09       Impact factor: 3.063

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.